These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21971618)

  • 21. Erythropoiesis stimulation in acute ischemic syndromes.
    Ruifrok WP; Lipsic E; de Boer RA; van Gilst WH; van Veldhuisen DJ
    Heart Fail Clin; 2010 Jul; 6(3):313-21. PubMed ID: 20630406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin in cancer-related anemia.
    Fenner MH; Ganser A
    Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors.
    Vukelic J; Dobrila-Dintinjana R; Jonjic N; Dekanic A; Ilijic V
    Med Hypotheses; 2013 Dec; 81(6):1155-8. PubMed ID: 24134826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human erythropoietin therapy in the surgical setting and applications in oncology.
    Goodnough LT
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):98-102. PubMed ID: 1928088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
    Beutel G; Ganser A
    Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
    Ford PA; Mastoris J
    Transfusion; 2004 Dec; 44(12 Suppl):15S-25S. PubMed ID: 15585001
    [No Abstract]   [Full Text] [Related]  

  • 30. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.
    Woodburn KW; Fan Q; Winslow S; Chen MJ; Mortensen RB; Casadevall N; Stead RB; Schatz PJ
    Exp Hematol; 2007 Aug; 35(8):1201-8. PubMed ID: 17662888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoietin: the swinging pendulum.
    Oster HS; Neumann D; Hoffman M; Mittelman M
    Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Erythropoietin--physiology and therapeutic potentialities].
    Möllmann M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1992 Dec; 27(8):461-8. PubMed ID: 1489869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of recombinant human erythropoietin in the treatment of anaemia of prematurity.
    Polkowska G; Wójcik-Skierucha E; Furmaga-Jabłońska W
    Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):178-83. PubMed ID: 16146073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of patients' responses to epoetin alfa therapy.
    Krantz SB
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer-related anaemia management in the 21st century.
    Pronzato P
    Cancer Treat Rev; 2006; 32 Suppl 2():S1-3. PubMed ID: 16725269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
    Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
    Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 39. Anemia management in oncology and hematology.
    Spivak JL; Gascón P; Ludwig H
    Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
    Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
    Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.